GlassScriptPhysician profile
Marshall Hutchison
NPI 1003385394
$2,861.87
in general payments reported to CMS, 2019-2025
6 companies · $1,333 in 2025
The $1,333 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $124 · 2022: $49.47 · 2023: $114 · 2024: $1,241 · 2025: $1,333.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,332 · Travel and Lodging: $1,116 · Consulting Fee: $225 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,331.56 |
| Travel and Lodging | $1,115.52 |
| Consulting Fee | $225.00 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $1,896.11 | 2023-2025 | Inspire |
| Glaxosmithkline, LLC. | $479.02 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Zoll Respicardia, INC. | $225.00 | 2025 | Remede System |
| Astrazeneca Pharmaceuticals LP | $118.86 | 2025 | Fasenra, Breztri |
| Axsome Therapeutics, INC. | $114.06 | 2025 | Sunosi |
| Genzyme Corporation | $28.82 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Hutchison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.